[Objectives] This study was conducted to understand the current status of duck related research. [Methods] CiteSpace knowledge graph analysis tool, VOSviewer visual analysis software and HistCite citation graph analys...[Objectives] This study was conducted to understand the current status of duck related research. [Methods] CiteSpace knowledge graph analysis tool, VOSviewer visual analysis software and HistCite citation graph analysis tool were used to analyze the number of publications and subject distribution of duck-related research fields in the Web of Science core collection database. The main countries(regions) and institutions, the main academic journals, the main research scholars, the main research hotspots and their changing trends were used for quantitative analysis. [Results](1) Duck-related research is receiving more and more attention, which further supports ducks’ important significance in the livestock and poultry industry.(2) Countries such as China, the United States, Canada, and France had published more articles in this field, and there was close cooperation between countries.(3) The top two journals with local citations in the duck-related research fields were PLOS ONE and JOURNAL OF VIROLOGY, and the journal with the highest impact factor in 2019 was JOURNAL OF VIROLOGY.(4) High-yield scholars in duck related research fields included Cheng Anchun, Wang Mingshu, Jia Renyong, etc.(5) Infection was a research hotspot in duck-related research. Typical pathogenic microorganisms included Newcastle disease, Avian influenza, and campylobacter.(6) The future trend of duck-related research mainly focuses on breeds, living environment, diseases, and molecular mechanisms. [Conclusions] Based on data from the Web of Science core collection database, this paper provides a complete bibliometric analysis of the current research status of ducks.展开更多
Background:Glecirasib,an inhibitor of Kirsten rat sarcoma viral oncogene homolog glycine-to-cysteine substitution at codon 12(KRAS G12C),has exhibited clinical activity in non-small-cell lung cancer(NSCLC)and colorect...Background:Glecirasib,an inhibitor of Kirsten rat sarcoma viral oncogene homolog glycine-to-cysteine substitution at codon 12(KRAS G12C),has exhibited clinical activity in non-small-cell lung cancer(NSCLC)and colorectal cancer(CRC).Here,we investigated the efficacy and safety of glecirasib in patients with pancreatic ductal adenocarcinoma(PDAC)and other solid tumors(excluding NSCLC and CRC)that rarely harbor the KRAS G12C mutation but for which effective treatment options remain limited.Methods:We conducted and analyzed two open-label,phase I/II trials in adult patients with KRAS G12C mutant solid tumors,in which glecirasib was administered orally.The two trials had similar eligibility criteria and endpoints but differed in the regions of patient recruitment.We performed a pooled analysis of all patients,excluding NSCLC and CRC,from both trials.The primary end-point in the pooled population was objective response rate(ORR).Efficacy and safety were assessed in patients who received at least one dose of glecirasib.Results:As of June 30,2024,the pooled analysis included 54 patients who were treated with glecirasib:32 PDACs,8 biliary tract cancers(BTCs),4 small intestinal cancers,3 gastric cancers,2 appendiceal cancers,and 5 other tumors.At baseline,24 received≥two prior lines of systemic therapy.Of the 53 efficacyevaluable patients,the confirmed ORR was 50.9%(95%confidence interval[CI],36.8%-64.9%),with an ORR of 46.9%(95%CI,29.1%-65.3%)in PDAC patients.Among other solid tumors,ORR was 71.4%(5/7)in BTC,100%(4/4)in small intestinal cancer,and 66.7%(2/3)in gastric cancer.Median progression-free survival and median overall survival were 6.9 and 10.8 months,respectively,in the overall population,and 5.5 and 10.8 months,respectively,in patients with PDAC.Treatment-related adverse events(TRAEs)of any grade occurred in 94.4%patients,with grade≥3 TRAEs in 27.8%.No fatal TRAEs or TRAEs leading to treatment discontinuation occurred.Conclusions:Glecirasib showed promising efficacy and was well tolerated in patients with PDAC and other advanced solid tumors(beyond NSCLC and CRC),warranting further expedited clinical development in this patient population.Trial registration:ClinicalTrials.gov identifier:NCT05009329 and NCT05002270.展开更多
Background:The ASTRUM-005 study previously demonstrated a signifi-cant overall survival(OS)benefit with serplulimab(a programmed death1 inhibitor)plus chemotherapy versus chemotherapy alone in previouslyuntreated exte...Background:The ASTRUM-005 study previously demonstrated a signifi-cant overall survival(OS)benefit with serplulimab(a programmed death1 inhibitor)plus chemotherapy versus chemotherapy alone in previouslyuntreated extensive-stage small-cell lung cancer(ES-SCLC).Here,we reportupdated efficacy and safety results after an extended median follow-up of 19.8months,along with the first report on findings from exploratory biomarkeranalyses.Methods:A total of 585 patients were randomized in a 2:1 ratio to receive4.5 mg/kg serplulimab(n=389)or placebo(n=196)intravenously every 3weeks,together with carboplatin and etoposide.The primary endpoint was OS.In addition,genomic profiling was performed to identify mutated genes,and quantitative serum proteome profiling was conducted to identify differ-entially expressed proteins(DEPs)between responders and non-responders ofserplulimab plus chemotherapy.Regression analysis was subsequently used toconstruct a protein signature based on the DEPs.The associations betweenefficacy outcomes(objective response rate[ORR],OS,and progression-free sur-vival[PFS])and gene mutation status or DEP expression were also examinedwith regression analysis.Furthermore,the prognostic value of hematologicalparameters was evaluated.Results:In the intent-to-treat population,the median OS was 15.8 monthsin the serplulimab group versus 11.1 months in the placebo group(haz-ard ratio,0.62;95%confidence interval,0.50-0.76;P<0.001).We identified181 DEPs between responders and non-responders in the serplulimab group,from which a 15-protein signature was constructed.In the serplulimab group,patients with a higher 15-protein signature score were associated with sig-nificantly longer OS and PFS.Also,patients harboring tumor-suppressorretinoblastoma-1(RB1)mutations or mutations in Notch pathway membersshowed improved ORR,OS,or PFS compared with their wild-type counter-parts.Baseline neutrophil-to-lymphocyte ratio(NLR)and lactate dehydrogenase(LDH)level were independent prognosticators of patients with ES-SCLC.Conclusions:First-line serplulimab provided a sustained clinical benefit overplacebo in patients with ES-SCLC.A 15-protein signature and mutations in RB1or Notch pathway genes may serve as predictive biomarkers for benefits fromserplulimab plus chemotherapy,while baseline NLR and LDH were independentprognosticators for ES-SCLC.展开更多
基金Supported by National Natural Science Foundation of China(31260607,31560703)Guizhou Provincial Hundred-level Innovative Talent Project(QKHRC20164009)Guizhou Provincial Science and Technology Platform and Talent Team Planning Project(QKHPTRC20185253)。
文摘[Objectives] This study was conducted to understand the current status of duck related research. [Methods] CiteSpace knowledge graph analysis tool, VOSviewer visual analysis software and HistCite citation graph analysis tool were used to analyze the number of publications and subject distribution of duck-related research fields in the Web of Science core collection database. The main countries(regions) and institutions, the main academic journals, the main research scholars, the main research hotspots and their changing trends were used for quantitative analysis. [Results](1) Duck-related research is receiving more and more attention, which further supports ducks’ important significance in the livestock and poultry industry.(2) Countries such as China, the United States, Canada, and France had published more articles in this field, and there was close cooperation between countries.(3) The top two journals with local citations in the duck-related research fields were PLOS ONE and JOURNAL OF VIROLOGY, and the journal with the highest impact factor in 2019 was JOURNAL OF VIROLOGY.(4) High-yield scholars in duck related research fields included Cheng Anchun, Wang Mingshu, Jia Renyong, etc.(5) Infection was a research hotspot in duck-related research. Typical pathogenic microorganisms included Newcastle disease, Avian influenza, and campylobacter.(6) The future trend of duck-related research mainly focuses on breeds, living environment, diseases, and molecular mechanisms. [Conclusions] Based on data from the Web of Science core collection database, this paper provides a complete bibliometric analysis of the current research status of ducks.
文摘Background:Glecirasib,an inhibitor of Kirsten rat sarcoma viral oncogene homolog glycine-to-cysteine substitution at codon 12(KRAS G12C),has exhibited clinical activity in non-small-cell lung cancer(NSCLC)and colorectal cancer(CRC).Here,we investigated the efficacy and safety of glecirasib in patients with pancreatic ductal adenocarcinoma(PDAC)and other solid tumors(excluding NSCLC and CRC)that rarely harbor the KRAS G12C mutation but for which effective treatment options remain limited.Methods:We conducted and analyzed two open-label,phase I/II trials in adult patients with KRAS G12C mutant solid tumors,in which glecirasib was administered orally.The two trials had similar eligibility criteria and endpoints but differed in the regions of patient recruitment.We performed a pooled analysis of all patients,excluding NSCLC and CRC,from both trials.The primary end-point in the pooled population was objective response rate(ORR).Efficacy and safety were assessed in patients who received at least one dose of glecirasib.Results:As of June 30,2024,the pooled analysis included 54 patients who were treated with glecirasib:32 PDACs,8 biliary tract cancers(BTCs),4 small intestinal cancers,3 gastric cancers,2 appendiceal cancers,and 5 other tumors.At baseline,24 received≥two prior lines of systemic therapy.Of the 53 efficacyevaluable patients,the confirmed ORR was 50.9%(95%confidence interval[CI],36.8%-64.9%),with an ORR of 46.9%(95%CI,29.1%-65.3%)in PDAC patients.Among other solid tumors,ORR was 71.4%(5/7)in BTC,100%(4/4)in small intestinal cancer,and 66.7%(2/3)in gastric cancer.Median progression-free survival and median overall survival were 6.9 and 10.8 months,respectively,in the overall population,and 5.5 and 10.8 months,respectively,in patients with PDAC.Treatment-related adverse events(TRAEs)of any grade occurred in 94.4%patients,with grade≥3 TRAEs in 27.8%.No fatal TRAEs or TRAEs leading to treatment discontinuation occurred.Conclusions:Glecirasib showed promising efficacy and was well tolerated in patients with PDAC and other advanced solid tumors(beyond NSCLC and CRC),warranting further expedited clinical development in this patient population.Trial registration:ClinicalTrials.gov identifier:NCT05009329 and NCT05002270.
基金Shanghai Henlius Biotech Inc.NationalNatural Science Foundation of China,Grant/Award Number:82473000。
文摘Background:The ASTRUM-005 study previously demonstrated a signifi-cant overall survival(OS)benefit with serplulimab(a programmed death1 inhibitor)plus chemotherapy versus chemotherapy alone in previouslyuntreated extensive-stage small-cell lung cancer(ES-SCLC).Here,we reportupdated efficacy and safety results after an extended median follow-up of 19.8months,along with the first report on findings from exploratory biomarkeranalyses.Methods:A total of 585 patients were randomized in a 2:1 ratio to receive4.5 mg/kg serplulimab(n=389)or placebo(n=196)intravenously every 3weeks,together with carboplatin and etoposide.The primary endpoint was OS.In addition,genomic profiling was performed to identify mutated genes,and quantitative serum proteome profiling was conducted to identify differ-entially expressed proteins(DEPs)between responders and non-responders ofserplulimab plus chemotherapy.Regression analysis was subsequently used toconstruct a protein signature based on the DEPs.The associations betweenefficacy outcomes(objective response rate[ORR],OS,and progression-free sur-vival[PFS])and gene mutation status or DEP expression were also examinedwith regression analysis.Furthermore,the prognostic value of hematologicalparameters was evaluated.Results:In the intent-to-treat population,the median OS was 15.8 monthsin the serplulimab group versus 11.1 months in the placebo group(haz-ard ratio,0.62;95%confidence interval,0.50-0.76;P<0.001).We identified181 DEPs between responders and non-responders in the serplulimab group,from which a 15-protein signature was constructed.In the serplulimab group,patients with a higher 15-protein signature score were associated with sig-nificantly longer OS and PFS.Also,patients harboring tumor-suppressorretinoblastoma-1(RB1)mutations or mutations in Notch pathway membersshowed improved ORR,OS,or PFS compared with their wild-type counter-parts.Baseline neutrophil-to-lymphocyte ratio(NLR)and lactate dehydrogenase(LDH)level were independent prognosticators of patients with ES-SCLC.Conclusions:First-line serplulimab provided a sustained clinical benefit overplacebo in patients with ES-SCLC.A 15-protein signature and mutations in RB1or Notch pathway genes may serve as predictive biomarkers for benefits fromserplulimab plus chemotherapy,while baseline NLR and LDH were independentprognosticators for ES-SCLC.
